May 8, 2024: On behalf of NCHR, Diana Zuckerman’s testimony at the House Small Business Committee explains that FDA regulations save lives and saves patients’ financial security and do not interfere with innovation in health care.
Read More »On Health Policy
NCHR Comment on Collection of Race and Ethnicity Data in Clinical Trials and Clinical Studies for FDA-Regulated Medical Products
April 29, 2024: NCHR backs FDA’s proposed guidance to collect standardized race/ethnicity data in clinical trials, which is crucial for addressing safety and efficacy disparities. We also urge a new category, mandatory implementation, and improved diversity to ensure accurate representation and meaningful efficacy and safety data
Read More »Patient, Consumer, and Public Health Coalition Letter to Rep. Pallone in Support of the Ban Water Beads Act (H.R. 6468)
May 1, 2024: We strongly support H.R. 6468 which would expedite the removal of water beads from the market to prevent severe injuries and fatalities due to these products.
Read More »Statement from Dr. Diana Zuckerman Regarding the FDA Final Rule on Regulation of Lab Developed Tests
April 29, 2024: We strongly support today’s FDA’s decision to regulate lab-developed tests. Unfortunately, FDA’s final rules has compromised on the critical issue of grandfathering thousands of tests on the already on the market.
Read More »NCHR Comments on CMS’ Proposed Rule On Strengthening the Oversight of Accrediting Organizations and Preventing Conflict of Interests, and Related Provisions
April 16th, 2024: NCHR supports CMS’ proposed rule and policies to increase oversight of Medicare accrediting organizations by addressing conflicts of interest; establishing standards, processes, and definitions for state surveys and unannounced surveys; and revising the validation survey program. We provide four key recommendations to bolster CMS’ proposal.
Read More »